TW202328114A - Glp-1受體激動劑的可藥用鹽、結晶形式及其製備方法 - Google Patents

Glp-1受體激動劑的可藥用鹽、結晶形式及其製備方法 Download PDF

Info

Publication number
TW202328114A
TW202328114A TW111149827A TW111149827A TW202328114A TW 202328114 A TW202328114 A TW 202328114A TW 111149827 A TW111149827 A TW 111149827A TW 111149827 A TW111149827 A TW 111149827A TW 202328114 A TW202328114 A TW 202328114A
Authority
TW
Taiwan
Prior art keywords
methyl
ray powder
characteristic peaks
compound
salt
Prior art date
Application number
TW111149827A
Other languages
English (en)
Chinese (zh)
Inventor
陸偉棟
徐穀軍
楊俊然
邵啟雲
杜振興
馮君
峰 賀
Original Assignee
大陸商江蘇恒瑞醫藥股份有限公司
大陸商上海恒瑞醫藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商江蘇恒瑞醫藥股份有限公司, 大陸商上海恒瑞醫藥有限公司 filed Critical 大陸商江蘇恒瑞醫藥股份有限公司
Publication of TW202328114A publication Critical patent/TW202328114A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/12—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to hydrocarbon groups substituted by hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW111149827A 2021-12-23 2022-12-23 Glp-1受體激動劑的可藥用鹽、結晶形式及其製備方法 TW202328114A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111584574 2021-12-23
CN202111584574.4 2021-12-23

Publications (1)

Publication Number Publication Date
TW202328114A true TW202328114A (zh) 2023-07-16

Family

ID=86901360

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111149827A TW202328114A (zh) 2021-12-23 2022-12-23 Glp-1受體激動劑的可藥用鹽、結晶形式及其製備方法

Country Status (11)

Country Link
US (1) US20250049777A1 (https=)
EP (2) EP4455141B1 (https=)
JP (1) JP2024547113A (https=)
KR (1) KR20240125003A (https=)
CN (1) CN118434730A (https=)
AU (1) AU2022418658A1 (https=)
CA (1) CA3241670A1 (https=)
DK (1) DK4455141T3 (https=)
MX (1) MX2024007906A (https=)
TW (1) TW202328114A (https=)
WO (1) WO2023116882A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120981457A (zh) 2023-09-14 2025-11-18 歌礼制药(中国)有限公司 Glp-1r激动剂及其治疗方法
TW202521534A (zh) 2023-11-24 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
WO2025148954A1 (zh) * 2024-01-09 2025-07-17 山东盛迪医药有限公司 一种glp-1r激动剂药物组合物及其应用
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
MA54555A (fr) * 2018-11-22 2021-09-29 Qilu Regor Therapeutics Inc Agonistes de glp-1r et leurs utilisations
CN115697338B (zh) * 2020-06-10 2024-08-09 东宝紫星(杭州)生物医药有限公司 甲基取代的苯并二噁唑类化合物及其应用
CA3188891A1 (en) * 2020-09-01 2022-01-13 Fanglong Yang Fused imidazole derivative, preparation method therefor, and medical use thereof
CN117177970A (zh) * 2021-04-30 2023-12-05 上海翰森生物医药科技有限公司 多环类衍生物调节剂、其制备方法和应用

Also Published As

Publication number Publication date
EP4732838A2 (en) 2026-04-29
MX2024007906A (es) 2024-07-10
AU2022418658A1 (en) 2024-07-11
CN118434730A (zh) 2024-08-02
EP4455141B1 (en) 2026-03-25
EP4455141A1 (en) 2024-10-30
DK4455141T3 (da) 2026-04-27
EP4455141A4 (en) 2025-04-09
CA3241670A1 (en) 2023-06-29
JP2024547113A (ja) 2024-12-26
US20250049777A1 (en) 2025-02-13
WO2023116882A1 (zh) 2023-06-29
KR20240125003A (ko) 2024-08-19

Similar Documents

Publication Publication Date Title
TW202328114A (zh) Glp-1受體激動劑的可藥用鹽、結晶形式及其製備方法
TWI905118B (zh) 作為prmt5抑制劑的取代三環類化合物及其應用
TW202328115A (zh) Glp-1受體激動劑的結晶形式及其製備方法
TW202521533A (zh) Glp-1r 激動劑及其治療方法
TW202542158A (zh) 稠環化合物、包含其的藥物組合物及其用途
TWI826013B (zh) 咪唑啉酮衍生物的晶型
WO2024046277A1 (zh) 一系列含氮桥杂环化合物及其制备方法
TW202043233A (zh) 1,2,3-三氮唑并[1,5-a]吡類衍生物的晶型及其製備方法
EP4291183B1 (en) Oxadiazolyl dihydropyrano[2,3-b]pyridine inhibitors of hipk2 for treating kidney fibrosis
CN112500353B (zh) 一种左西孟旦的前药化合物、制备方法及其应用
CN118355000A (zh) 二甲基亚磺酰亚胺衍生物的盐型及晶型
WO2022127904A1 (zh) 一种吲唑类衍生物的药学上可接受的盐、结晶形式及其制备方法
HU226059B1 (en) Novel disubstituted trans-3,4,4a,5,6,10b-hexahydro-2h-naphto[1,2-b][1,4]oxazine derivatives, process for producing them and pharmaceutical compositions containing them
TW202116741A (zh) 噻唑烷二酮衍生物以及包含其的藥物組成物
TWI914461B (zh) 一種吲唑類衍生物的藥學上可接受鹽、結晶形式及其製備方法
WO2025031459A9 (zh) 一种氮杂麦角林类衍生物、其药物组合物和其应用
CN116437917A (zh) Atx抑制剂氘代衍生物及其应用
TW202333694A (zh) 稠環衍生物的晶型、其製備方法及其應用
WO2023151660A1 (zh) 一种p2x3受体拮抗剂的结晶形式及其制备方法
WO2025180517A1 (zh) 含sf5类喹啉衍生物及其作为p2x7拮抗剂的用途
TW202434600A (zh) 磺醯胺衍生物結晶形式及其製備方法
WO2025131045A1 (zh) 一种taar1配体激动剂的盐型、晶型及其制备方法和应用
CN119798232A (zh) N-甲酰胺基吡唑啉化合物的晶型及其制备方法和应用
CN117945945A (zh) 一种gpr139受体激动剂、其制备方法及其应用